Methotrexate High-Dose PK Simulator
Indication: Cancer/RA
Interactive high-dose methotrexate PK simulator for oncology regimens and toxicity monitoring. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, and the simulator tracks IV exposure with clinically relevant toxicity thresholds at 24, 48, and 72 hours.
Drug Overview
Clinical Context
- Molecular Target
- Dihydrofolate reductase (DHFR)
- Drug Class
- Antimetabolite
- Therapeutic Area
- Oncology
- Indication
- Cancer/RA
- Route of Administration
- IV
Model Information
- Model Type
- popPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Methotrexate High-Dose allows you to explore concentration-time profiles under different dosing scenarios. The underlying popPK model characterizes the pharmacokinetics of this antimetabolite following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Methotrexate High-Dose PK simulator?
This is a free, interactive pharmacokinetic simulator for Methotrexate High-Dose used in Cancer/RA. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Methotrexate High-Dose belong to?
Methotrexate High-Dose is classified as a Antimetabolite that targets Dihydrofolate reductase (DHFR). It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Methotrexate High-Dose. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a popPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
Capecitabine and 5-FU
Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
PBPK-PD of ADCs
Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy
Ready to Simulate?
Launch the Methotrexate High-Dose simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community